Share

2020 Hindsight: Adjusting for an Unexpected Year

While most organizations would have found 2020 a challenging year, the Endocrine Society’s Adrenal and Pituitary Special Interest Group managed to thrive with the help of new technology, expert staff guidance, and a group of determined members.   The Endocrine Society’s Adrenal and Pituitary Special Interest Group (AP-SIG) was created to connect physicians and scientists...
Share

No Two Ways About It: Reconceptualizing Type 2 Diabetes

Drawing on years of prior research, a new paper published recently in The Journal of Clinical Endocrinology & Metabolism makes the case for a wider classification of a complex disease such as type 2 diabetes. A new series of subsets would take into account race, age at onset, and a host of other contributing factors....
Share

Over the Edge: Is COVID-19 Introducing a New Type of Diabetes?

Researchers are exploring the complex, push-pull relationship between COVID-19 and diabetes. Is the virus truly the cause of a new type of diabetes or is it merely hastening an inevitable development in susceptible patients?   From the earliest days of the COVID-19 pandemic, its effects on glycemic control have been among its challenges. Patients with...
Share

Phase 3 Trial Results Show Promise for Drug to Treat Severe Hypoglycemia

Earlier this week Diabetes Care published results from a Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. Zealand Pharma is marketing the drug as Zegalogue. The study found that dasiglucagon administration resulted in a reversal of hypoglycemia (with a median recovery time of 10 minutes) with 99% of...